Key result
HER2-targeted therapies should be continued despite LV dysfunction when cancer benefits outweigh cardiac risks.
Why the study?
How should cardiac dysfunction be managed and monitored in patients receiving HER2-targeted therapies for metastatic breast cancer?
How should cardiac dysfunction be managed and monitored in patients receiving HER2-targeted therapies for metastatic breast cancer?
Provides a practical, risk-benefit algorithm for surveillance and management of cardiotoxicity in patients receiving multiple lines of modern HER2-targeted therapy for metastatic breast cancer.
Supports continuing HER2 therapy in LV dysfunction via risk-benefit; leaves open prospective validation of algorithms.
• Targeted therapies improve clinical outcomes in HER2+ metastatic breast cancer. • There is thus far minimal signal of increased risk of cardiotoxicity from novel HER2 targeted therapies. • Cancer therapy benefit drives clinical decision-making with LV dysfunction. • The frequency of cardiac monitoring should be based on a risk-benefit approach.
No takes yet. Share an insight, caveat, or question.
Dent et al. (2022) conducted a review in Metastatic HER2-Positive Breast Cancer with left ventricular dysfunction. HER2-targeted therapies was evaluated. HER2-targeted therapies should be continued based on a risk-benefit approach where cancer therapy benefit drives clinical decision-making even in the presence of left ventricular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: